InterCure (INCR)
NASDAQ:INCR
INCR Stock Chart & Stats
$0.98
$0.04(2.22%)
At close: 4:00 PM EST
$0.98
$0.04(2.22%)
Day’s Range― - ―
52-Week Range$0.68 - $1.77
Previous CloseN/A
Volume20.32K
Average Volume (3M)105.31K
Market Cap
$69.57M
Enterprise Value$332.85M
Total Cash (Recent Filing)$51.58M
Total Debt (Recent Filing)$179.34M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding54,681,335
10 Day Avg. Volume49,383
30 Day Avg. Volume105,312
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market Cap4.78
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit8.20
Enterprise Value/Ebitda-4.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationThe shift to positive operating and free cash flow in 2025 reflects improved working-capital management and spending discipline. Durable cash generation enhances financial flexibility, reduces refinancing risk, and funds ongoing cultivation, product development and retail operations without reliance on external equity.
Revenue ReboundAn 11.1% revenue rebound signals recovering demand or better commercial execution across wholesale and retail channels. Sustained top-line growth supports scale benefits, higher capacity utilization and the potential to improve gross margins and profitability over the medium term if the trend persists.
Manageable LeverageA sub-0.5 debt-to-equity ratio and improvement year-over-year indicate a moderate leverage profile. This level of indebtedness preserves borrowing capacity and keeps interest burden manageable, supporting capital expenditure for cultivation and retail expansion while limiting immediate solvency risks.
Bears Say
Persistent Net LossesThree consecutive years of net losses and a negative 2025 net margin show the business has not yet converted revenue growth into sustainable profitability. Continued losses can erode equity, constrain reinvestment and force reliance on external capital if cash-generation gains weaken.
Multi-year Negative ROERepeated negative ROE indicates the company is not generating acceptable returns on shareholder capital. This structural weakness undermines investor confidence, can raise the cost of new equity, and signals that operational improvements must sustain to avoid long-term dilution or balance-sheet erosion.
Compressed Gross MarginsA marked compression in gross margin versus prior years reduces the firm's ability to absorb SG&A, invest in growth, or withstand input-cost volatility. If margin pressure is structural (pricing, mix or cost inflation), it materially limits the pathway to consistent operating profitability.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was $0.68 and its highest was $1.77 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is $69.57M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is Aug 17, 2026 which is in 76 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -$0.216 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.216.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 54,681,335 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -$0.216 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.843%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
Technical Analysis
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.59% Other Institutional Investors
99.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---